9 Lenzer J. Anticoagulants cause the most serious adverse events, finds US analysis. BMJ. 2012; 344: e3989.
10 Centers for Disease Control and Prevention. Tobacco-Related Mortality. Available online at: www.cdc.gov/tobacco/data_statistics/fact_sheets/health_effects/tobacco_related_mortality/ (accessed 2 February 2013).
11 Iyer S, Naganathan V, McLachlan AJ, et al. Medication withdrawal trials in people aged 65 years and older: a systematic review. Drugs Aging. 2008; 25: 1021–31.
12 Petersen M. Our Daily Meds. New York: Sarah Crichton Books; 2008.
13 Rennie D. When evidence isn’t: trials, drug companies and the FDA. J Law Policy. 2007 July: 991–1012.
14 Kassirer JP. On the Take: how medicine’s complicity with big business can endanger your health. Oxford: Oxford University Press; 2005.
15 Smith R. The Trouble with Medical Journals. London: Royal Society of Medicine; 2006.
16 Brownlee S. Overtreated: why too much medicine is making us sicker and poorer. New York: Bloomsbury; 2007.
17 World Health Organization. World Health Report 2003 – shaping the future. 2003. Available online at: www.who.int/whr/2003/annex_4_en.xls (accessed 20 December 2012).
18 Reinhardt UE, Hussey PS, Anderson GF. U.S. health care spending in an international context. Health Aff (Millwood). 2004; 23: 10–25.
19 Roehr B. Health care in US ranks lowest among developed countries, Commonwealth Fund study shows. BMJ. 2008; 337: a889.
20 Starfield B, Shi L, Grover A, et al. The effects of specialist supply on populations’ health: assessing the evidence. Health Aff (Millwood). 2001 March 15. DOI: 10.1377/hlthaff.w5.97.
21 World Health Organization. The World Medicines Situation. Available online at: http://apps.who.int/medicinedocs/en/d/Js6160e/6.html#Js6160e.6 (accessed 6 February 2013).
22 Wealth but not health in the USA. Lancet. 2013; 381: 177.
23 Nolte E, McKee CM. Measuring the health of nations: updating an earlier analysis. Health Aff (Millwood). 2008; 27: 58–71.
24 Avendano M, Glymour MM, Banks J, et al. Health disadvantage in US adults aged 50 to 74 years: a comparison of the health of rich and poor Americans with that of Europeans. Am J Public Health. 2009; 99: 540–8.
25 Jachuck SJ, Brierley H, Jachuck S, et al. The effect of hypotensive drugs on the quality of life. J R Coll Gen Pract. 1982; 32: 103–5.
26 Krogsbøll LT, Jørgensen KJ, Grønhøj Larsen C, et al. General health checks for reducing morbidity and mortality from disease. Cochrane Database Syst Rev. 2012; 10: CD009009.
27 Johnston ME, Gibson ES, Terry CW, et al. Effects of labelling on income, work and social function among hypertensive employees. J Chronic Dis. 1984; 37: 417–23.
28 Butt DA, Mamdani M, Austin PC, et al. The risk of hip fracture after initiating antihypertensive drugs in the elderly. Arch Intern Med. 2012; 172: 1739–44.
29 Abramson J. Overdo$ed America. New York: HarperCollins; 2004.
30 Oliver M. Let’s not turn elderly people into patients. BMJ. 2009; 338: b873.
31 Cacciotti J, Clinton P. Pharm Exec 50: growth from the bottom up. Pharmaceutical Executive. 2012 May 1. Available online at: www.pharmexec.com/pharmexec/Noteworthy/Pharm-Exec-50-Growth-from-the-Bottom-Up/ArticleStandard/Article/detail/773562 (accessed 17 July 2013).
32 Berwick DM, Hackbarth, A. Eliminating waste in US health care. JAMA. 2012; 307: 1513–16.
33 Liberati A, Magrini N. Information from drug companies and opinion leaders. BMJ. 2003; 326: 1156–7.
34 Tanne JH. US healthcare executives hit pay jackpot. BMJ. 2011; 343: d8330.
35 Whelton RS. Effects of Excessive CEO Pay on U.S. Society. Available online at: www.svsu.edu/emplibrary/Whelton%20article.pdf (accessed 6 November 2007).
36 Schafer A. Biomedical conflicts of interest: a defence of the sequestration thesis – learning from the cases of Nancy Olivieri and David Healy. J Med Ethics. 2004; 30: 8–24.
37 Relman A. A Second Opinion: rescuing America’s health care. New York: Public Affairs; 2007.
38 Krimsky S. Science in the Private Interest: has the lure of profits corrupted biomedical research? Lanham: Rowman & Littlefield; 2003.
39 Braithwaite J. Corporate Crime in the Pharmaceutical Industry. London: Routledge & Kegan Paul; 1984.
40 Goozner M. The $800 Million Pill: the truth behind the cost of new drugs. Berkeley: University of California Press; 2005.
41 Abraham J. Science, Politics and the Pharmaceutical Industry. London: UCL Press; 1995.
42 Day M. MRC says it will invent, develop, and market its own drugs. BMJ. 2007; 334: 1025.
43 Bloemen S, Hammerstein D. Time for the EU to lead on innovation. Health Action International Europe and Trans Atlantic Consumer Dialogue. 2012 April.
44 Bassand J-P, Martin J, Rydén L, et al. The need for resources for clinical research: The European Society of Cardiology calls for European, international collaboration. Lancet. 2002; 360: 1866–9.
45 Gøtzsche PC, Hansen M, Stoltenberg M, et al. Randomized, placebo controlled trial of withdrawal of slow-acting antirheumatic drugs and of observer bias in rheumatoid arthritis. Scand J Rheumatol. 1996; 25: 194–9.
46 Relman AS, Angell M. America’s other drug problem: how the drug industry distorts medicine and politics. The New Republic. 2002 Dec 16: 27–41.
47 Gøtzsche PC. Blinding during data analysis and writing of manuscripts. Controlled Clin Trials. 1996; 17: 285–90.
48 Borst-Eilers E. Assessing hospital technology in the Netherlands: new treatments are paid for only if they are part of an evaluation. BMJ. 1993; 306: 226.
49 Garattini S, Bertele V. How can we regulate medicines better? BMJ. 2007; 335: 803–5.
50 Liberati A, Traversa G, Moja LP, et al. Feasibility and challenges of independent research on drugs: the Italian Medicines Agency (AIFA) experience. Eur J Clin Invest. 2010; 40: 69–86.
51 Light DW, Lexchin JR. Pharmaceutical research and development: what do we get for all that money? BMJ. 2012; 344: e4348.
52 Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346: 393–403.
53 Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA. 2001; 285: 437–43.
54 Savulescu J, Chalmers I, Blunt J. Are research ethics committees behaving unethically? Some suggestions for improving performance and accountability. BMJ. 1996; 313: 1390–3.
55 Goldbeck-Wood S. Denmark takes a lead on research ethics. BMJ. 1998; 316: 1189.
56 Goldacre B. Bad Pharma. London: Fourth Estate; 2012.
57 Lundh A, Krogsbøll LT, Gøtzsche PC. Access to data in industry-sponsored trials. Lancet. 2011; 378: 1995–6.
58 Lundh A, Krogsbøll LT, Gøtzsche PC. Sponsors’ participation in conduct and reporting of industry trials: a descriptive study. Trials. 2012; 13: 146.
59 Heran BS, Wong MMY, Heran IK, et al. Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database Syst Rev. 2008; 4: CD003823.
60 Directive 2010/84/EU of the European Parliament and of the Council. 2010 Dec 15.
61 Gøtzsche PC, Liberati A, Luca P, et al. Beware of surrogate outcome measures. Int J Technol Ass Health Care. 1996; 12: 238–46.
62 Apolone G, Joppi R, Bertele V, et al. Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures. Br J Cancer. 2005; 93: 504–9.
63 Garattini S, Bertele V. Efficacy, safety, and cost of new anticancer drugs. BMJ. 2002; 325: 269–71.
64 Machin D, Stenning SP, Parmar MKB, et al. Thirty years of Medical Research Council randomized trials in solid tumours. Clin Oncol. 1997; 9: 100–14.
65 Soares HP, Kumar A, Daniels S, et al. Evaluation of new treatments in radiation oncology: are they better than standard treatments? JAMA. 2005; 293: 970–8.
66
Kumar A, Soares H, Wells R, et al. Are experimental treatments for cancer in children superior to established treatments? Observational study of randomised controlled trials by the Children’s Oncology Group. BMJ. 2005; 331: 1295–8.
67 Avorn J. Powerful Medicines: the benefits, risks, and costs of prescription drugs. New York: Vintage Books; 2005.
68 Rochon PA, Fortin PR, Dear KB, et al. Reporting of age data in clinical trials of arthritis. Deficiencies and solutions. Arch Intern Med. 1993; 153: 243–8.
69 Van Spall HG, Toren A, Kiss A, et al. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA. 2007; 297: 1233–40.
70 Cerreta F, Eichler HG, Rasi G. Drug policy for an aging population – the European Medicines Agency’s geriatric medicines strategy. N Engl J Med. 2012; 367: 1972–4.
71 World Medical Association. Ethical Principles for Medical Research Involving Human Subjects. 2008. Available online at: www.wma.net/en/30publications/10policies/b3/ (accessed 17 July 2013).
72 Whitaker R. Anatomy of an Epidemic. New York: Random House; 2010.
73 Strom BL. How the US drug safety system should be changed. JAMA. 2006; 295: 2072–5.
74 Ray WA, Stein CM. Reform of drug regulation – beyond an independent drug-safety board. N Engl J Med. 2006; 354: 194–201.
75 Newman M. Bitter pills for drug companies. BMJ. 2010; 341: c5095.
76 Alsman SW. [Hidden research led to wrong recommendations about happy pills]. Økonomisk Ugebrev. 2004 May 3.
77 Senate Republican Policy Committee. Legislative Notice No. 13. S. 1082 – The FDA Revitalization Act. Available online at: http://rpc.senate.gov/_files/L13S1082FDARevitalizationAct043007KP.pdf (accessed 30 October 2007).
78 Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD 28 monoclonal antibody TGN 1412. N Engl J Med. 2006; 355: 1018–28.
79 Lenzer J, Brownlee S. An untold story? BMJ. 2008; 336: 532–4.
80 Gøtzsche PC. Why we need easy access to all data from all clinical trials and how to accomplish it. Trials. 2011; 12: 249.
81 Danish Medicines Agency. [Danish Medicines Agency’s Performance Contract 2007 – 2010]. Available online at: www.laegemiddelstyrelsen.dk/db/filarkiv/6653/resultatkontrakt2007_2010.pdf (accessed 15 August 2008).
82 Okie S. Safety in numbers – monitoring risk in approved drugs. N Engl J Med. 2005; 352: 1173–6.
83 Carlsen LT. [A difficult balance]. Tænk + Test. 2003; 32: 30–3.
84 Mundy A. Dispensing with the Truth. New York: St. Martin’s Press; 2001.
85 Schwartz LM, Woloshin S, Welch HG. Using a drug facts box to communicate drug benefits and harms: two randomized trials. Ann Intern Med. 2009; 150: 516–27.
86 Woloshin S, Schwartz LM, Welch HG. Know your Chances: understanding health statistics. Berkely: University of California Press; 2008.
87 Woloshin S, Schwartz LM. Think inside the box. New York Times. 2011 July 4.
88 Chren MM, Landefeld CS. Physicians’ behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary. JAMA. 1994; 271: 684–9.
89 Brennan TA, Rothman DJ, Blank L et al. Health industry practices that create conflicts of interest: a policy proposal for academic medical centers. JAMA. 2006; 295: 429–33.
90 Tougaard H, Hundevadt K. [The golden promises of the gynaecologists]. Jyllandsposten. 2004 Jan 18.
91 Fugh-Berman A, McDonald CP, Bell AM, et al. Promotional tone in reviews of menopausal hormone therapy after the women’s health initiative: an analysis of published articles. PLoS Med. 2011; 8: e1000425.
92 Singer N. Medical papers by ghostwriters pushed therapy. New York Times. 2009 Aug 4.
93 Rosenberg M. Pfizer’s ghostwritten journal articles are still standing, still bogus. Online Journal. 2010 Feb 23.
94 Gøtzsche PC. Mammography Screening: truth, lies and controversy. London: Radcliffe Publishing; 2012.
95 Conflicts of interest in biomedical research. Canada’s Voice for Academics. 2003; 50: Feb.
96 Elliott C. Pharma goes to the laundry: public relations and the business of medical education. Hastings Cent Rep. 2004; 34: 18–23.
97 Willman D. How a new policy led to seven deadly drugs. Los Angeles Times. 2000 Dec 20.
98 Bindslev JB, Schroll J, Gøtzsche PC, et al. Underreporting of conflicts of interest in clinical practice guidelines: cross-sectional study. BMC Med Ethics. 2013; 14: 19.
99 Steinbrook R. Controlling conflict of interest – proposals from the Institute of Medicine. N Engl J Med. 2009; 360: 2160–3.
100 Zinner DE, Bolcic-Jankovic D, Clarridge B, et al. Participation of academic scientists in relationships with industry. Health Aff. 2009; 28: 1814–25.
101 Lenzer J. French guidelines are pulled over potential bias among authors. BMJ. 2011; 342: d4007.
102 Clinard MB, Yeager PC. Corporate Crime. New Brunswick: Transaction Publishers; 2006.
103 Reuters. Factbox – The 20 largest pharmaceutical companies. 2010 Mar 26. Available online at: www.reuters.com/article/2010/03/26/pharmaceutical-mergers-idUSN2612865020100326 (accessed 17 June 2012).
104 Wikipedia. List of countries by GDP (nominal). Available online at: http://en.wikipedia.org/wiki/List_of_countries_by_GDP_(nominal) (accessed 30 June 2012).
105 Annas GJ. Corporations, profits, and public health. Lancet. 2010; 376: 583–4.
106 Thomas K, Schmidt MS. Glaxo agrees to pay $3 billion in fraud settlement. New York Times. 2012 July 2.
107 Khan H, Thomas P. Drug giant AstraZeneca to pay $520 million to settle fraud case. ABC News. 2010 April 27.
108 Brynner R, Stephens T. Dark Remedy: the impact of thalidomide and its revival as a vital medicine. New York: Perseus Publishing; 2001.
109 House of Commons Health Committee. The Influence of the Pharmaceutical Industry. Fourth Report of Session 2004–05. Available online at: www.publications.parliament.uk/pa/cm200405/cmselect/cmhealth/42/42.pdf (accessed 26 April 2005).
110 Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA. 2000; 283: 373–80.
111 Grill M. Kranke Geschäfte: wie die Pharmaindustrie uns manipuliert. Hamburg: Rowohlt Verlag; 2007.
112 Ziegler MG, Lew P, Singer BC. The accuracy of drug information from pharmaceutical sales representatives. JAMA. 1995; 273: 1296–8.
113 Dana J, Loewenstein G. A social science perspective on gifts to physicians from industry. JAMA. 2003; 290: 252–5.
114 Moynihan R, Heath I, Henry D. Selling sickness: the pharmaceutical industry and disease mongering. BMJ. 2002; 324: 886–91.
115 Campbell EG. Doctors and drug companies: scrutinizing influential relationships. N Engl J Med. 2007; 357: 1796–7.
116 Steinman MA, Shlipak MG, McPhee SJ. Of principles and pens: attitudes and practices of medicine housestaff toward pharmaceutical industry promotions. Am J Med. 2001; 110: 551–7.
117 Brody H. Hooked: ethics, the medical profession, and the pharmaceutical industry. Lanham: Rowman & Littlefield; 2008.
118 Campbell EG, Gruen RL, Mountford J, et al. A national survey of physician-industry relationships. N Engl J Med. 2007; 356: 1742–50.
119 Lenzer J. Many US medical associations and disease awareness groups depend heavily on funding by drug manufacturers. BMJ. 2011; 342: d2929.
120 Campbell EG, Weissman JS, Ehringhaus S, et al. Institutional academic industry relationships. JAMA. 2007; 298: 1779–86.
121 Revill J. Doctor accuses drug giant of ‘unethical’ secrecy. Observer. 2005 Dec 4.
122 Steinbrook R. Physician-industry relations – will fewer gifts make a difference? N Engl J Med. 2009; 360: 557–9.
123 Roehr B. US Institute of Medicine report calls for an end to firms’ drug and device promotion to doctors. BMJ. 2009; 338: 1100.
124 Steinman MA, Landefeld CS, Baron RB. Industry support of CME – are we at the tipping point? N Engl J Med.
2012; 366: 1069–71.
125 Norris SL, Holmer HK, Ogden LA, et al. Characteristics of physicians receiving large payments from pharmaceutical companies and the accuracy of their disclosures in publications: an observational study. BMC Medical Ethics. 2012; 13: 24.
126 Arnfred CE, Pedersen LN, Agger C. [Politicians feel cheated by lobby-doctors]. Jyllandsposten. 2011 Aug 29.
127 Thirstrup S. [Can you sell diseases]? Rationel Farmakoterapi. 2010 Dec.
128 Borg O. [Pill ads are distributed in school yards]. Jyllands-Posten. 2011 Nov 1.
129 Herxheimer A. Relationships between the pharmaceutical industry and patients’ organisations. BMJ. 2003; 326: 1208–10.
130 Rathje M. [Heart Association scares the Danes]. TV2 News. 2012 April 20.
131 Cassidy J. The International Alliance of Patients’ Organizations. BMJ. 2011; 342: d3485.
132 [Danish Association of the Pharmaceutical Industry’s collaboration with patient associations and others in 2010]. 2010. Available online at: www.lifdk.dk/graphics/Lif/Inside%20Lif/2011/09/Medlemmers%20samarbejde%20med%20patientforeninger%20m.v.%202010.pdf (accessed 28 June 2011).
133 Wolfe S. The seven-year rule for safer prescribing. Aust Prescr. 2012; 35: 138–9.
134 Jelinek GA, Brown AF. A stand against drug company advertising. Emergency Medicine Australasia. 2011; 23: 4–6.
135 Altman DG. The scandal of poor medical research: we need less research, better research, and research done for the right reasons. BMJ. 1994; 308: 283–4.
136 Lexchin J, Light DW. Commercial influence and the content of medical journals. BMJ. 2006; 332: 1444–7.
137 Lundh A, Barbateskovic M, Hróbjartsson A, et al. Conflicts of interest at medical journals: the influence of industry-supported randomised trials on journal impact factors and revenue – cohort study. PLoS Med. 2010; 7: e1000354.
138 Smith R, Roberts I. Patient safety requires a new way to publish clinical trials. PLoS Clin Trials. 2006; 1: e6.
139 Clinical knowledge: from access to action. Lancet. 2008; 371: 785.
140 Schwartz L, Woloshin S, Moynihan R. Who’s watching the watchdogs? BMJ. 2008; 337: a2535.
Deadly Medicines and Organised Crime Page 50